康辰药业(603590) - 2020 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter was CNY 70.93 million, down 63.20% year-on-year[6] - Net profit attributable to shareholders was CNY 32.23 million, a decline of 34.45% compared to the same period last year[6] - The company reported a significant decline in revenue and profit, indicating challenges in the current market environment[6] - Total revenue for Q1 2020 was CNY 70,929,823.49, a decrease of 63.20% compared to CNY 192,747,541.50 in the same period last year, primarily due to the impact of COVID-19 on surgical patient numbers[13] - Net profit for Q1 2020 was CNY 32,233,485.04, down 34.45% from CNY 49,170,649.65 in the previous year, primarily due to reduced sales revenue[13] - Operating profit decreased by 33.01% to CNY 37,159,105.11 from CNY 55,469,888.49, reflecting the impact of decreased sales revenue[13] - The total profit for Q1 2020 was ¥34,823,835.70, a decrease of 35.1% from ¥53,682,218.26 in Q1 2019[27] - The total comprehensive income for Q1 2020 was ¥50,581,809.80, a decrease of 46.0% from ¥93,656,398.50 in Q1 2019[27] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 61.32 million, representing a decrease of 9.65% year-on-year[6] - Cash flow from investing activities showed a net outflow of CNY -171,778,858.90, an increase of 151.61% compared to CNY -68,271,450.30 in the same period last year, primarily due to increased purchases of structured deposits[13] - Cash and cash equivalents as of March 31, 2020, were CNY 1,727,016,573.43, an increase from CNY 1,672,921,734.51 at the end of 2019[21] - The ending balance of cash and cash equivalents was CNY 1,327,786,489.04, down from CNY 1,552,964,669.62 at the end of the previous year[35] - The net increase in cash and cash equivalents was -CNY 110,550,215.67, compared to -CNY 49,959,349.61 in the same quarter last year[35] Assets and Liabilities - Total assets at the end of the reporting period were approximately CNY 3.12 billion, a decrease of 1.65% compared to the end of the previous year[6] - Total assets as of March 31, 2020, amounted to CNY 3,123,876,558.21, a slight decrease from CNY 3,175,288,377.29 at the end of 2019[23] - Total liabilities decreased to CNY 329,248,572.13 in Q1 2020 from CNY 431,242,201.01 in Q1 2019, reflecting a reduction of approximately 23.7%[22] - Total liabilities amounted to ¥445,844,690.19, with current liabilities at ¥330,096,514.62 and non-current liabilities at ¥115,748,175.57[37] - Total equity reached ¥2,727,998,110.33, including paid-in capital of ¥160,000,000.00 and retained earnings of ¥1,475,321,111.62[37] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,806[10] - The largest shareholder, Liu Jianhua, held 31.74% of the shares, totaling 50,786,760 shares[10] Inventory and Receivables - Accounts receivable decreased by 39.69% to CNY 130,322,970.34 from CNY 216,089,946.44, mainly due to the collection of receivables during the period[12] - Inventory increased by 50.84% to CNY 21,499,721.76 from CNY 14,253,542.64, attributed to an increase in raw materials, work-in-progress, and finished goods[12] - The company reported a significant decrease in accounts receivable, which fell to CNY 126,950,632.54 from CNY 212,166,896.10 in the previous year, a reduction of approximately 40%[21] Research and Development - Research and development expenses for Q1 2020 were CNY 13,624,824.45, down from CNY 18,225,015.70 in Q1 2019, indicating a 25.5% reduction[24] - Research and development expenses for Q1 2020 were ¥13,624,824.45, a decrease of 23.4% from ¥17,830,655.92 in Q1 2019[26] Other Financial Metrics - Basic and diluted earnings per share were both CNY 0.20, down 35.48% from CNY 0.31 in the previous year[6] - Other comprehensive income increased by 63.03% to CNY 50,302,962.94 from CNY 30,854,596.95, mainly due to changes in the fair value of other equity investments[12] - Tax payable decreased by 71.33% to CNY 8,756,412.35 from CNY 30,540,713.55, mainly due to a reduction in VAT and income tax payable at the end of the period[12] - The company incurred sales expenses of ¥32,217,546.98 in Q1 2020, down 73.8% from ¥123,148,262.63 in Q1 2019[26]